Injectsense announces first human implant of ultraminiature IOP sensor

News
Article

Injectsense's future plans for the sensor are to fine-tune its delivery tool and incorporate a microbattery into the sensor.

IOP detecting sensor and its applicator Image credit: Injectsense

Image credit: Injectsense

Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.1 The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.

"From a physician's perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment," said Mura in the release. "It's extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7."

Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.1

"Although safety is the primary focus of this study, we are also informing our product design to meet the expectations of ophthalmologists across the globe," said Ariel Cao, President/CEO of Injectsense. "We expect these sensors to be easily delivered in the doctor's office."

In November 2023, Injectsense announced that it secured $9.4 million in funding with sister company Injectpower to bring the implantable device into production.2

References:
  1. Injectsense completes first human implantation of its ultraminiaturized intraocular pressure sensor. PR Newswire. News release. August 27, 2024. Accessed August 28, 2024. https://www.prnewswire.com/news-releases/injectsense-completes-first-human-implantation-of-its-ultraminiaturized-intraocular-pressure-sensor-302231827.html
  2. Injectsense and solid-state microbattery partner Injectpower secure $9.4 million for implantable device supply chain and support of clinical studies. Injectsense. News release. November 15, 2023. Accessed August 28, 2024. https://www.injectsense.com/1-7m-sbir-grant
Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
© 2025 MJH Life Sciences

All rights reserved.